These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33636938)

  • 41. Idylla assay and next generation sequencing: an integrated EGFR mutational testing algorithm.
    De Luca C; Rappa AG; Gragnano G; Malapelle U; Troncone G; Barberis M
    J Clin Pathol; 2018 Aug; 71(8):745-750. PubMed ID: 29798838
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.
    Sakai K; Tsurutani J; Yamanaka T; Yoneshige A; Ito A; Togashi Y; De Velasco MA; Terashima M; Fujita Y; Tomida S; Tamura T; Nakagawa K; Nishio K
    PLoS One; 2015; 10(5):e0121891. PubMed ID: 25954997
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Frequency and coexistence of KRAS, NRAS, BRAF and PIK3CA mutations and occurrence of MMR deficiency in Danish colorectal cancer patients.
    Poulsen TS; de Oliveira DVNP; Espersen MLM; Klarskov LL; Skovrider-Ruminski W; Hogdall E
    APMIS; 2021 Feb; 129(2):61-69. PubMed ID: 33075161
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon Cancer.
    Korphaisarn K; Pongpaibul A; Roothumnong E; Pongsuktavorn K; Thamlikitkul L; Anekpuritanang T; Poungvarin N; Thongnoppakhun W; Pithukpakorn M
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2319-2326. PubMed ID: 31450901
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer.
    Gökmen İ; Taştekin E; Demir N; Özcan E; Akgül F; Hacıoğlu MB; Erdoğan B; Topaloğlu S; Çiçin İ
    Curr Issues Mol Biol; 2023 Sep; 45(10):7803-7812. PubMed ID: 37886935
    [TBL] [Abstract][Full Text] [Related]  

  • 47. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
    Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
    Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Correlation between
    Bożyk A; Krawczyk P; Reszka K; Krukowska K; Kolak A; Mańdziuk S; Wojas-Krawczyk K; Ramlau R; Milanowski J
    Arch Med Sci; 2022; 18(5):1221-1230. PubMed ID: 36160343
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System.
    Janku F; Huang HJ; Claes B; Falchook GS; Fu S; Hong D; Ramzanali NM; Nitti G; Cabrilo G; Tsimberidou AM; Naing A; Piha-Paul SA; Wheler JJ; Karp DD; Holley VR; Zinner RG; Subbiah V; Luthra R; Kopetz S; Overman MJ; Kee BK; Patel S; Devogelaere B; Sablon E; Maertens G; Mills GB; Kurzrock R; Meric-Bernstam F
    Mol Cancer Ther; 2016 Jun; 15(6):1397-404. PubMed ID: 27207774
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An Automated Real-Time PCR Assay versus Next-Generation Sequencing in the Detection of
    Lenders D; Bonzheim I; Hahn M; Gassenmaier M; Aebischer V; Forschner A; Lenders MM; Flatz L; Forchhammer S
    Diagnostics (Basel); 2024 Jul; 14(15):. PubMed ID: 39125519
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of an optimal mutant allele frequency to detect activating
    Caughey BA; Umemoto K; Green MF; Ikeda M; Lowe ME; Ueno M; Niedzwiecki D; Taniguchi H; Walden DJ; Komatsu Y; D'Anna R; Esaki T; Denda T; Datto MB; Bando H; Bekaii-Saab T; Yoshino T; Strickler JH; Nakamura Y
    J Gastrointest Oncol; 2023 Oct; 14(5):2083-2096. PubMed ID: 37969845
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Performance evaluation of a fully closed real-time PCR platform for the detection of KRAS p.G12C mutations in liquid biopsy of patients with non-small cell lung cancer.
    Gragnano G; Nacchio M; Sgariglia R; Conticelli F; Iaccarino A; De Luca C; Troncone G; Malapelle U
    J Clin Pathol; 2022 May; 75(5):350-353. PubMed ID: 33649142
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rapid and reliable testing for clinically actionable EGFR mutations in non-small cell lung cancer using the Idylla
    Michaelidou K; Karniadakis I; Pantelaion V; Koutoulaki C; Boukla E; Folinas K; Dimaras P; Papadaki MA; Koutsopoulos AV; Mavroudis D; Vourlakou C; Mavridis K; Agelaki S
    Expert Rev Mol Diagn; 2024; 24(1-2):89-98. PubMed ID: 38193169
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Combined detection of KRAS, NRAS, BRAF and PIK3CA mutations in the plasma and tumor tissues of colorectal cancer patients].
    Liu XN; Tian Z; Wei XF; Wang Q; Zhang JX; Jin MS; Duan XM
    Zhonghua Bing Li Xue Za Zhi; 2019 May; 48(5):373-377. PubMed ID: 31104677
    [No Abstract]   [Full Text] [Related]  

  • 55. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples.
    Vivancos A; Aranda E; Benavides M; Élez E; Gómez-España MA; Toledano M; Alvarez M; Parrado MRC; García-Barberán V; Diaz-Rubio E
    Sci Rep; 2019 Jun; 9(1):8976. PubMed ID: 31222012
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Automated PCR detection of BRAF mutations in colorectal adenocarcinoma: a diagnostic test accuracy study.
    Colling R; Wang LM; Soilleux E
    J Clin Pathol; 2016 May; 69(5):398-402. PubMed ID: 26537294
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
    Modest DP; Ricard I; Heinemann V; Hegewisch-Becker S; Schmiegel W; Porschen R; Stintzing S; Graeven U; Arnold D; von Weikersthal LF; Giessen-Jung C; Stahler A; Schmoll HJ; Jung A; Kirchner T; Tannapfel A; Reinacher-Schick A
    Ann Oncol; 2016 Sep; 27(9):1746-53. PubMed ID: 27358379
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular testing in metastatic colorectal adenocarcinoma cytology cell pellets.
    McHugh KE; Dermawan JK; Cheng YW; Cruise M; Sohal DPS; Reynolds JP
    Diagn Cytopathol; 2019 Nov; 47(11):1132-1137. PubMed ID: 31290252
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.